ManerMed Sp z o.o.
- Address
- Ul. Garbary 5/l4, 85-229 Bydgoszcz, Poland
Digestive System Diseases
At ManerMed Sp z o.o. in Bydgoszcz, Poland, research in digestive system diseases focuses mainly on inflammatory bowel disease, including Crohn’s disease, ulcerative colitis, and related forms of gastrointestinal inflammation. These studies are designed to test new therapies, compare treatment options, and better understand how to improve symptom control and long-term disease management.
- Evaluating new treatments for Crohn’s disease and ulcerative colitis
- Comparing investigational medicines with established therapies for inflammatory bowel disease
- Assessing remission, response, and durable disease control in gastrointestinal disorders
- Studying therapies for related conditions such as erosive esophagitis due to GERD
The site is active in both induction and maintenance research, reflecting a strong interest in helping patients achieve faster symptom relief and sustained control of chronic digestive conditions.
Immune System Diseases
Clinical trials in immune system diseases at this site are centered on disorders driven by abnormal immune activity, especially ulcerative colitis and Crohn’s disease. The research aims to evaluate whether targeted therapies can reduce inflammation, improve clinical remission rates, and offer safer or more effective options for people living with chronic immune-mediated disease.
- Testing targeted therapies for immune-mediated inflammation
- Studying treatment effectiveness in moderately to severely active ulcerative colitis
- Assessing new approaches for moderately to severely active Crohn’s disease
- Exploring long-term safety and tolerability of emerging immunology treatments
This research portfolio includes studies of both single therapies and combination approaches, with an emphasis on finding better options for patients whose disease remains active despite standard care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 28 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International9trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in ManerMed Sp z o.o.
lock Showing 1 of 39 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1 Study of Afimkibart Effects on Cytochrome P450-Mediated Drug Metabolism in Patients With Active Ulcerative Colitis | F. Hoffmann-La Roche AG | Phase I | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 28 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Guselkumab | 6 | Unknown | 2019-10-19 | 2026-05-28 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.